ArticleActa dermato-venereologica2025
Bidirectional Risk Association Between Hidradenitis Suppurativa and Inflammatory Bowel Disease.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hidradenitis suppurativa: epidemiology, diagnosis, molecular pathogenesis and therapy.Molecular biomedicine · 2026Review
- The Genetics of Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2026Review
- Pharmacomicrobiomics in inflammatory skin diseases: past, present, and the future.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa is an inflammatory skin disease of the pilosebaceous unit encompassing painful, recurrent, and malodorous abscesses, inflammatory nodules, dermal sinus tracts, and cicatrices. Hidradenitis suppurativa has been linked to several comorbidities, including inflammatory bowel disease, though evidence is limited by small sample sizes and possible bidirectional associations remain uncertain. A large-scale, propensity-score matched retrospective cohort study was performed using the TriNetX platform to investigate bidirectional risks between hidradenitis suppurativa and inflammatory bowel disease. Data included over 200,000 hidradenitis suppurativa patients and 3.3 million inflammatory bowel disease patients. Hidradenitis suppurativa was associated with a 36% increased risk of developing any inflammatory bowel disease diagnosis within 5 years of diagnosis (hazard ratio [HR] 1.356, confidence interval [CI] 1.313-1.401), with the highest risk of Crohn's disease (HR 2.501, CI 2.209-2.832), followed by ulcerative colitis (UC) (HR 1.722, CI 1.536-1.930), and other/unspecified inflammatory bowel disease (HR 1.349, CI 1.306-1.394). Conversely, individuals with any inflammatory bowel disease diagnosis had a 31% increased risk of developing hidradenitis suppurativa (HR 1.313, CI 1.274-1.353), with Crohn's disease showing the strongest association (HR 2.441, CI 2.242-2.658), followed by UC (HR 1.493, CI 1.358-1.642). These findings highlight the bidirectional risk relationship between hidradenitis suppurativa and inflammatory bowel disease, demonstrating that the likelihood of developing either condition is significantly elevated in patients already diagnosed with the other.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.